Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Proficio Capital Partners LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 30.2% in the fourth ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Declining sales of Trulicity and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds. (You can read the full research report on Eli Lilly here >>>) Shares of ...

Declining sales of Trulicity, rising pricing pressure on ... (You can read the full research report on Eli Lilly here >>>) Shares of S&P Global have outperformed the Zacks Business - Information ...

Its primary revenue drivers are the diabetes drugs Humalog (1996) and Trulicity (2014). Since the beginning of the year, one insider made 24 sales of Eli Lilly and Company (NYSE:LLY) shares.

In the field of diabetes care, Lilly’s Humalog and Trulicity have been major revenue drivers. Eli Lilly and Company (NYSE:LLY) was also the first to mass-produce both the polio vaccine and insulin.